Investigational drug · Phase 2
CTO1681
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cytokine Release Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CTO1681"
First trial start
2023
Dec 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTO1681", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cytokine Release Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CTO1681" as an intervention, largest first.
- Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell TherapyRecruiting
CytoAgents, Inc.Industry
NCT05905328 · 54 participants (planned) · Start Dec 28, 2023 · Primary completion Jun 2027
Drug: CTO1681 10 µg; CTO1681 20 μg and 3 more · For: Cytokine Release Syndrome
Sites: Orange, California; Augusta, Georgia; Boston, Massachusetts · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.